Table 4 |
||||||||
|
Baseline and 3-month and 6-month tocilizumab therapy evaluation criteria in eight patients with peripheral spondyloarthritis |
||||||||
|
Patient 14 |
Patient 15 |
Patient 16 |
Patient 17 |
Patient 18 |
Patient 19 |
Patient 20 |
Patient 21 |
|
|
|
||||||||
|
DAS28 |
||||||||
|
M0 |
4.02 |
4.52 |
5 |
4.58 |
5.41 |
6.2 |
5.23 |
4.92 |
|
M3 (absolute value) |
2.82 |
3.85 |
4.3 |
2.88 |
3.18 |
1.1 |
5.1 |
4.70 |
|
M3 EULAR response (yes/no) |
Yes (good) |
No |
Yes (moderate) |
Yes (good) |
Yes (good) |
Yes (remission) |
No |
No |
|
M6 (absolute value) |
1.95 |
4.01 |
5.34 |
3.12 |
NA |
NA |
NA |
NA |
|
M6 EULAR response (yes/no) |
Yes (remission) |
No |
No |
Yes (good) |
NA |
NA |
NA |
NA |
|
ASDAS |
||||||||
|
M0 |
2.41 |
4.03 |
MD |
MD |
MD |
3.8 |
3 |
MD |
|
M3 (absolute value) |
1.50 |
2.64 |
MD |
MD |
MD |
1.35 |
3.1 |
MD |
|
M6 (absolute value) |
1.03 |
2.79 |
MD |
MD |
MD |
NA |
NA |
MD |
|
SJCa |
||||||||
|
M0 |
7 |
2 |
2 |
0 |
3 |
9 |
4 |
7 |
|
M3 (absolute value) |
NA |
NA |
NA |
NA |
7 |
0 |
3 |
6 |
|
M6 (absolute value) |
0 |
6 |
1 |
0 |
NA |
NA |
NA |
NA |
|
TJCa |
||||||||
|
M0 |
7 |
6 |
5 |
5 |
0 |
15 |
7 |
12 |
|
M3 (absolute value) |
NA |
NA |
NA |
NA |
0 |
0 |
6 |
11 |
|
M6 (absolute value) |
2 |
4 |
3 |
8 |
NA |
NA |
NA |
NA |
|
BASDAI, 0 to 100 |
||||||||
|
M0 |
42 |
75 |
NA |
79.4 |
67 |
48 |
4.7 |
NA |
|
M3 (change from M0; %) |
-31 |
-6.7 |
NA |
-9 |
+6 |
NA |
-2.1 |
NA |
|
M6 (change from M0; %) |
-59.5 |
-4.7 |
NA |
-32 |
NA |
NA |
NA |
NA |
|
BASFI, 0 to 100 |
||||||||
|
M0 |
40 |
72 |
MD |
MD |
54 |
70 |
NA |
NA |
|
M3 (change from M0, %) |
-17.5 |
-26 |
MD |
MD |
+44 |
NA |
NA |
NA |
|
M6 (change from M0, %) |
-12.5 |
-12.5 |
MD |
MD |
NA |
NA |
NA |
NA |
|
Pain VAS, 0 to 10 |
||||||||
|
M0 |
1.5 |
7 |
5 |
7 |
7 |
5 |
6 |
8 |
|
M3 (absolute value) |
2 |
8 |
NA |
6 |
8 |
1 |
6.5 |
6 |
|
M6 (absolute value) |
1 |
9 |
6 |
7.5 |
NA |
NA |
NA |
NA |
|
PGA, 0 to 10 |
||||||||
|
M0 |
1 |
6 |
7 |
7.5 |
7 |
5.2 |
6.5 |
8 |
|
M3 (absolute value) |
3.5 |
6 |
MD |
MD |
7 |
1 |
6.5 |
8 |
|
M6 (absolute value) |
1.2 |
6 |
8 |
MD |
NA |
NA |
NA |
NA |
|
CRP (mg/dl)a |
||||||||
|
M0 |
20.2 |
17 |
119 |
12 |
112.3 |
65 |
4 |
1 |
|
M3 (absolute value) |
NA |
NA |
NA |
NA |
9.5 |
1 |
5 |
1 |
|
M6 (absolute value) |
0.4 |
0.8 |
128 |
1 |
NA |
NA |
NA |
NA |
|
ESR (mm)a |
||||||||
|
M0 |
39 |
22 |
67 |
26 |
103 |
60 |
27 |
7 |
|
M3 (absolute value) |
NA |
NA |
NA |
NA |
8 |
4 |
7 |
8 |
|
M6 (absolute value) |
5 |
7 |
70 |
2 |
NA |
NA |
NA |
NA |
|
|
||||||||
|
ASDAS, Assessment of SpondyloArthritis International Society endorsed disease activity score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; M0, month 0 (baseline); M3, month 3; M6, month 6; NA, not available; MD, missing data; PGA, patient's global assessment of disease activity; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. aFor SJC, TJC, CRP, and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6). |
||||||||
|
Lekpa et al. Arthritis Research & Therapy 2012 14:R53 doi:10.1186/ar3766 |
||||||||
